Stock AnalizNektar Therapeutics NKTR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Nektar Therapeutics (NKTR) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to September 30, 2026 it had revenue of $52M and net income of -$177M, a net margin of -339.7%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -18% a year, a 5-year average ROIC of -70%.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52M | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.2B | $308M | $165M |
| Net income | -$177M | -$164M | -$119M | -$276M | -$368M | -$524M | -$444M | -$441M | $681M | -$97M | -$154M |
| Free cash flow | -$257M | -$209M | -$177M | -$193M | -$310M | -$428M | -$321M | -$355M | $704M | -$90M | -$123M |
| EPS (diluted) | $-5.25 | $-4.87 | $-4.34 | $-10.87 | $-14.77 | $-21.45 | $-18.67 | $-18.90 | $28.35 | $-4.65 | $-8.25 |
| Net margin | -339.7% | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% |
| ROIC | — | -79.7% | -64.3% | -105.9% | -59.7% | -42.8% | -27.4% | -19.2% | 34.9% | -14.0% | -26.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $131.92, 254% above the current price; targets range from $40.00 to $192.00; the consensus rating is “Buy”; expected EPS is $-7.21 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Nektar Therapeutics pay a dividend?
Not currently.
Is Nektar Therapeutics a good stock to buy?
We do not give buy or sell advice. Nektar Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.